Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies

We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just b...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine case reports 2020-01, Vol.31, p.101272, Article 101272
Main Authors: Yanagihara, Toyoshi, Suzuki, Kunihiro, Egashira, Ayaka, Ogo, Naruhiko, Asoh, Tatsuma, Nara, Tsukasa, Takatsuki, Kensaku, Yoshizawa, Seiji, Chong, Sy Giin, Hamada, Naoki, Maeyama, Takashige
Format: Article
Language:English
Subjects:
Anti-ARS antibody
Case Report
Clinically amyopathic dermatomyositis
Nintedanib
Progressive fibrosing interstitial lung disease
Rapidly progressive interstitial lung disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just been approved for treatment of progressive fibrosing ILD, but to date, no reports of RP-ILD treated with nintedanib have been published. This case report may advance discussions regarding the use and timing of nintedanib in treating RP-ILD.
ISSN:2213-0071
2213-0071
DOI:10.1016/j.rmcr.2020.101272